Disarm Therapeutics
VerifiedCreating breakthrough therapeutics to treat patients with neurological diseases by preventing axonal degeneration.
Launch date
Market cap
-
Net debt
-
Enterprise valuation
$120—180m (Dealroom.co estimates Sep 2017.)
Cambridge Massachusetts (HQ)
Get premium to view all results
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | $0.0 | round | |
| investor investor investor | $0.0 | round | |
$135m | Acquisition | ||
| Total Funding | 000k | ||
RELATED LANDSCAPES AND LISTS
Related Content
Recent News about Disarm Therapeutics
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.